News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyclacel Pharmaceuticals, Inc. (CYCC) Provides Update On Its Clinical Development Plan Of Sapacitabine For Myelodysplastic Syndromes (MDS)


6/2/2014 9:46:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., May 31, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced plans for the clinical development of sapacitabine in a second potential indication for patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES